Ds-5141b (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
113 | Muscular dystrophy | 2 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04433234 (ClinicalTrials.gov) | July 8, 2020 | 12/6/2020 | Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy | A Phase II, Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy | Drug: DS-5141b | Daiichi Sankyo Co., Ltd. | NULL | Enrolling by invitation | 5 Years | N/A | Male | 8 | Phase 2 | Japan |
2 | NCT02667483 (ClinicalTrials.gov) | October 2015 | 26/1/2016 | Study of DS-5141b in Patients With Duchenne Muscular Dystrophy | Phase I/II Study of DS-5141b: Open-label Study of DS-5141b in Patients With Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy | Drug: DS-5141b | Daiichi Sankyo Co., Ltd. | Orphan Disease Treatment Institute Co., Ltd. | Active, not recruiting | 5 Years | 10 Years | Male | 7 | Phase 1;Phase 2 | Japan |